Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof

一种受体激动剂、透明质酸的技术，应用在干眼症的治疗,制造干眼症治疗剂中的应用,眼科用剂,P2Y2受体激动剂和透明质酸或其盐领域

Inactive Publication Date: 2013-05-08
SANTEN PHARMA CO LTD
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as described in the Dictionary of Pharmaceutical Additives, 220 (2007) (Non-Patent Document 5), the maximum amount of hyaluronic acid that can be used as an additive in ophthalmic preparations is 0.2 mg / g (0.02% (w / w)), for the combination of hyaluronic acid and P2Y at a therapeutically effective concentration (0.1% (w / v) or more as eye drops) 2 Eye drops of receptor agonists, not recorded or implied at all

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof
  • Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof
  • Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0180] [Pharmacological Test 1]

[0181] Changes in tear fluid storage can be evaluated by measuring the area of ​​the curved surface of the tear river stained with a fluorescein solution (Exp. Eye. Res., 78(3), 399-407(2004)). Therefore, according to the method of Murakami et al. (Ophthalmic Res., 34, 371-374 (2002)), normal male white rabbits were used to evaluate as P2Y 2 Time-dependent changes in the area of ​​the lacrimal surface after continuous instillation of receptor agonists diquafosol sodium and sodium hyaluronate.

[0182] (drug preparation method)

[0183] Dissolve 30 mg of diquafosol sodium in phosphate buffer, add potassium chloride, sodium chloride, benzalkonium chloride, and a pH regulator to prepare 1 mL of an isotonic and neutral aqueous solution, which is used as 3% diquafosol Phosphorus sodium eye drops were used in this experiment. It should be noted that "soft santear" manufactured by Santen Pharmaceutical Co., Ltd. was used as artificial tears, and "...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is an agent for the treatment of dry eye, which is characterized by combining a P2Y2 receptor agonist at a therapeutically effective concentration with hyaluronic acid or a salt thereof at a therapeutically effective concentration. This agent for the treatment of dry eye, which is in the form of an ophthalmic agent, remarkably promotes tear secretion and remarkably improves corneal epithelial disorder, and is thus expected to be a novel agent for the treatment of dry eye.

Description

technical field [0001] The invention relates to a therapeutic agent for dry eye syndrome, which is characterized in that P2Y with a therapeutically effective concentration 2 The combination of receptor agonist and therapeutically effective concentration of hyaluronic acid or its salt is obtained, and the dosage form is an ophthalmic agent. In addition, the present invention also relates to the use of such P2Y 2 Treatment of dry eye with agonists and hyaluronic acid or salts thereof. In addition, the present invention also relates to P2Y for use in the treatment of dry eye 2 A receptor agonist and hyaluronic acid or a salt thereof. Furthermore, the present invention also relates to such P2Y 2 Application of receptor agonist and hyaluronic acid or its salt in the manufacture of dry eye treatment agent. Background technique [0002] Dry eye syndrome is a disease that starts with uncomfortable symptoms such as dryness and dryness of the eyes. Once it worsens, it will cause ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/675A61K31/728A61P27/02
CPCA61K31/675A61K31/728A61K31/7072A61K31/7076A61K31/7068A61K45/06A61P27/02A61P27/04A61P43/00A61K2300/00A61K9/0048
Inventor 七条优子堂田敦义长野敬中村雅胤阪元明日香
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap